Editas Medicine, Inc. (EDIT)
3.08
+0.01
(+0.33%)
USD |
NASDAQ |
Sep 02, 16:00
3.06
-0.02
(-0.65%)
Pre-Market: 20:00
Editas Medicine Cash from Investing (Quarterly) : -29.80M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -29.80M |
| March 31, 2026 | 0.064M |
| December 31, 2025 | 0.058M |
| September 30, 2025 | 39.57M |
| June 30, 2025 | 42.65M |
| March 31, 2025 | 56.39M |
| December 31, 2024 | 30.96M |
| September 30, 2024 | 83.98M |
| June 30, 2024 | 51.95M |
| March 31, 2024 | -4.745M |
| December 31, 2023 | 62.84M |
| September 30, 2023 | -102.82M |
| June 30, 2023 | 12.98M |
| March 31, 2023 | 23.27M |
| December 31, 2022 | -27.53M |
| September 30, 2022 | 89.23M |
| June 30, 2022 | -4.002M |
| March 31, 2022 | 56.37M |
| December 31, 2021 | -22.84M |
| September 30, 2021 | -39.66M |
| June 30, 2021 | 4.791M |
| March 31, 2021 | 3.244M |
| December 31, 2020 | -108.89M |
| Date | Value |
|---|---|
| September 30, 2020 | -152.26M |
| June 30, 2020 | 74.17M |
| March 31, 2020 | 46.46M |
| December 31, 2019 | 7.818M |
| September 30, 2019 | -122.30M |
| June 30, 2019 | 76.11M |
| March 31, 2019 | 50.63M |
| December 31, 2018 | -8.604M |
| September 30, 2018 | -13.62M |
| June 30, 2018 | -71.68M |
| March 31, 2018 | 40.82M |
| December 31, 2017 | 26.68M |
| September 30, 2017 | -28.85M |
| June 30, 2017 | -180.98M |
| March 31, 2017 | -0.656M |
| December 31, 2016 | -0.656M |
| September 30, 2016 | -0.713M |
| June 30, 2016 | -1.161M |
| March 31, 2016 | -2.562M |
| December 31, 2015 | -0.401M |
| September 30, 2015 | -0.19M |
| June 30, 2015 | -0.535M |
| March 31, 2015 | -0.305M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Recursion Pharmaceuticals, Inc. | -1.959M |
| Geron Corp. | 8.295M |
| Halozyme Therapeutics, Inc. | -62.66M |
| Novavax, Inc. | 34.90M |
| AVITA Medical, Inc. | 3.947M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -29.57M |
| Cash from Financing (Quarterly) | 117.54M |
| Free Cash Flow | -120.55M |
| Free Cash Flow Per Share (Quarterly) | -0.2487 |
| Free Cash Flow to Equity (Quarterly) | -28.95M |
| Free Cash Flow to Firm (Quarterly) | -28.61M |
| Free Cash Flow Yield | -38.70% |